Biosimilars Education Act (S. 164)

Summary

Directs the government to create a website and materials to teach doctors and patients about biosimilar drugs, which are like generic versions of biologics.

What problem does this solve?

Doctors and patients may not understand biosimilar drugs, which can be cheaper than brand-name versions. This law requires creating educational materials to build trust and encourage their use, potentially lowering drug costs.

What does this law do?

Creates an educational website

Directs the government to run a website with materials for doctors, patients, and caregivers about biological products, including biosimilars.

Defines educational content

Specifies that the website must explain key terms like 'biosimilar' and 'interchangeable', how the drugs are developed, and how to report side effects.

Advances continuing education for providers

Requires the government to help create or improve continuing education programs for healthcare providers about prescribing these products.

Offers materials in multiple formats

Allows educational materials to be provided in various formats like webinars, videos, and fact sheets to suit different audiences.

Protects company secrets

Ensures that the educational efforts do not lead to the public release of trade secrets or confidential business information from drug manufacturers.

Who does this affect?

Healthcare providers
Patients using biological medicines
Caregivers

What is the real world impact?

•

Improves patient and doctor understanding

Provides clear, government-sourced information about biosimilar and interchangeable drugs to help patients and doctors make informed decisions about treatment options.

•

Promotes the use of lower-cost drugs

Encourages wider acceptance and use of biosimilars, which are often cheaper than brand-name biologics. This can help lower overall healthcare spending for patients, insurance companies, and the government.

When does this start?

The requirements of this law took effect on April 23, 2021.